Corebridge Financial Inc. Has $24.68 Million Position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Corebridge Financial Inc. trimmed its stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 5.0% during the fourth quarter, according to its most recent disclosure with the SEC. The fund owned 34,652 shares of the biopharmaceutical company's stock after selling 1,838 shares during the quarter. Corebridge Financial Inc.'s holdings in Regeneron Pharmaceuticals were worth $24,684,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors also recently modified their holdings of the company. Willner & Heller LLC grew its position in Regeneron Pharmaceuticals by 3.9% in the 4th quarter. Willner & Heller LLC now owns 399 shares of the biopharmaceutical company's stock valued at $284,000 after buying an additional 15 shares in the last quarter. OLD Second National Bank of Aurora boosted its holdings in shares of Regeneron Pharmaceuticals by 0.5% in the fourth quarter. OLD Second National Bank of Aurora now owns 2,843 shares of the biopharmaceutical company's stock valued at $2,025,000 after acquiring an additional 15 shares in the last quarter. Rakuten Securities Inc. increased its stake in shares of Regeneron Pharmaceuticals by 62.5% during the fourth quarter. Rakuten Securities Inc. now owns 39 shares of the biopharmaceutical company's stock valued at $28,000 after acquiring an additional 15 shares during the period. TD Private Client Wealth LLC raised its holdings in Regeneron Pharmaceuticals by 9.6% during the fourth quarter. TD Private Client Wealth LLC now owns 171 shares of the biopharmaceutical company's stock worth $122,000 after purchasing an additional 15 shares in the last quarter. Finally, Manchester Capital Management LLC boosted its stake in Regeneron Pharmaceuticals by 12.6% during the 4th quarter. Manchester Capital Management LLC now owns 161 shares of the biopharmaceutical company's stock valued at $115,000 after purchasing an additional 18 shares in the last quarter. Institutional investors and hedge funds own 83.31% of the company's stock.

Remove Ads

Analyst Upgrades and Downgrades

A number of research firms recently commented on REGN. Canaccord Genuity Group downgraded shares of Regeneron Pharmaceuticals from a "strong-buy" rating to a "hold" rating in a report on Tuesday, December 17th. Canaccord Genuity Group began coverage on shares of Regeneron Pharmaceuticals in a research report on Tuesday, December 17th. They set a "hold" rating and a $165.00 price objective on the stock. Citigroup decreased their target price on Regeneron Pharmaceuticals from $795.00 to $750.00 and set a "neutral" rating for the company in a research report on Tuesday, January 28th. Bank of America reissued an "underperform" rating and issued a $565.00 price objective on shares of Regeneron Pharmaceuticals in a research note on Tuesday, December 10th. Finally, Piper Sandler dropped their target price on Regeneron Pharmaceuticals from $1,195.00 to $1,013.00 and set an "overweight" rating on the stock in a report on Monday, January 27th. One investment analyst has rated the stock with a sell rating, six have given a hold rating, seventeen have given a buy rating and two have given a strong buy rating to the stock. Based on data from MarketBeat, the company has an average rating of "Moderate Buy" and an average price target of $973.13.

Regeneron Pharmaceuticals Price Performance

Shares of Regeneron Pharmaceuticals stock traded up $2.26 during trading on Friday, hitting $638.09. 82,493 shares of the company's stock traded hands, compared to its average volume of 640,035. Regeneron Pharmaceuticals, Inc. has a twelve month low of $629.02 and a twelve month high of $1,211.20. The company has a debt-to-equity ratio of 0.09, a current ratio of 4.73 and a quick ratio of 3.95. The company has a market cap of $69.76 billion, a PE ratio of 16.69, a PEG ratio of 2.34 and a beta of 0.27. The firm's fifty day moving average price is $684.76 and its 200 day moving average price is $803.87.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last issued its earnings results on Tuesday, February 4th. The biopharmaceutical company reported $12.07 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $11.21 by $0.86. The business had revenue of $3.79 billion during the quarter, compared to analysts' expectations of $3.76 billion. Regeneron Pharmaceuticals had a return on equity of 16.32% and a net margin of 31.07%. Regeneron Pharmaceuticals's quarterly revenue was up 10.3% compared to the same quarter last year. During the same period in the prior year, the firm posted $11.86 EPS. Analysts forecast that Regeneron Pharmaceuticals, Inc. will post 35.92 earnings per share for the current year.

Regeneron Pharmaceuticals Announces Dividend

The company also recently announced a quarterly dividend, which was paid on Thursday, March 20th. Stockholders of record on Thursday, February 20th were issued a $0.88 dividend. This represents a $3.52 annualized dividend and a dividend yield of 0.55%. The ex-dividend date of this dividend was Thursday, February 20th. Regeneron Pharmaceuticals's payout ratio is 2.30%.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.